Long-Term Effects of Intravitreal Infliximab for Treatment of Sight-Threatening Chronic Noninfectious Uveitis
- 6 September 2012
- journal article
- research article
- Published by SAGE Publications in Journal of Ocular Pharmacology and Therapeutics
- Vol. 28 (6) , 628-631
Abstract
Purpose: This study aimed to evaluate the safety and long-term effects of infliximab on chronic noninfectious uveitis with measuring best corrected visual acuity (BCVA) and central macular thickness (CMT). Method: Ten eyes of 7 patients were included in this prospective case series. All the patients had noninfectious anterior and posterior uveitis that was unresponsive to conventional treatments for 3 months. About 1.5 mg of infliximab in 0.15 cc was injected intravitreally and the patients were followed for 6 months. BCVA was measured by Snellen chart and grading of vitritis was measured according to binocular indirect ophthalmoscope score before injection, 4 weeks, 3 months, and 6 months after the injection. CMT was measured 1 day before injection and compared with the same factors 4 weeks and 6 months after the injection. Results: Mean of LogMAR before injection was 1.37±0.43 that changed to 0.67±0.55 and 1.38±0.36 one month and 6 months after the injection, respectively. Mean CMT before injection was 673.2±338.39 that changed to 456.4±317.46 and 659.3±342.48, 4 weeks and 6 months after the injection, respectively. Mean vitreous haziness grade before injection, 4 weeks, 3 months, and 6 months after the injection was 2.7, 0.95, 2.3, and 2.6, respectively. Conclusions: Intravitreal Infliximab may be used in treatment of noninfectious uveitis. It probably improves the vision and decreases the macular edema but its effect is temporary and repeated injections may be needed to achieve the best therapeutic goal.Keywords
This publication has 17 references indexed in Scilit:
- INTRAVITREAL INFLIXIMAB FOR THE TREATMENT OF SIGHT-THREATENING CHRONIC NONINFECTIOUS UVEITISRetina, 2010
- Anti-TNF-α Treatment: A Possible Promoter in Endogenous Uveitis? Observational Report on Six Patients: Occurrence of Uveitis Following Etanercept TreatmentCurrent Eye Research, 2010
- Treatment of Primary Sjögren SyndromeJAMA, 2010
- Relationship between serum infliximab levels and acute uveitis attacks in patients with Behcet diseaseBritish Journal of Ophthalmology, 2010
- Comparison of the Acute Effects of anti-TNF-alpha Drugs on a Uveitis Experimental ModelOcular Immunology and Inflammation, 2010
- The First Decade of Biologic TNF Antagonists in Clinical Practice: Lessons Learned, Unresolved Issues and Future Directions2010
- ADVERSE EVENTS AFTER INTRAVITREAL INFLIXIMAB (REMICADE)Retina, 2010
- Intravitreal Infliximab in Experimental Endotoxin-Induced UveitisEuropean Journal of Ophthalmology, 2009
- Intravitreal Administration of the Anti-Tumor Necrosis Factor Agent Infliximab for Neovascular Age-related Macular DegenerationAmerican Journal of Ophthalmology, 2009
- TNFα blockade in human diseases: An overview of efficacy and safetyClinical Immunology, 2008